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Abstract
Objective:  we  objective  to  present  the  experience  on  prenatal  diagnosis  of  1p36
terminal  deletion,  and  further  delineated  the  fetal  presentation  of  the  syndrome.
Materials and methods: This was a retrospective analysis of three new prenatal cases
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with  pure  1p36  terminal  deletion  detected  by  chromosome  microarray  analysis
(CMA)  at  a  single  Chinese  medical  center.  We  also  reviewed  11  published
prenatal  cases  with  similar  deletion  sizes. Clinical  data  of  all  cases
including indications for invasive testing, sonographic findings, maternal factors, and
pregnancy outcomes were reviewed and analyzed. Results: Three new cases with pure
1p36 terminal deletion were prenatal diagnosed by CMA, the sizes of the deletion
were 1.3 Mb, 5.0 Mb, and 4.9 Mb respectively. All cases were detected because of
abnormal ultrasound findings, including central nervous system (CNS) abnormalities,
congenital heart disease (CHD) and fetal growth restriction. Two pregnancies were
terminated, and one was live-born but died three months after birth. Conclusions: The
1p36 terminal deletion results in many clinical manifestations, but the specificity of
clinical features are not high. Prenatal sonographic findings such as CNS, CHD may
act  as  suggestive  signs  of  1p36  deletion  or  other  microdeletion/duplication
syndromes. 
Keywords:  Prenatal  diagnosis;  1p36  terminal  deletion;  Chromosomal  microarray
analysis; Prenatal ultrasound findings
Introduction
Chromosome  1p36  deletion  syndrome  (OMIM  607872)  is  the  most  common
subtelomeric  terminal  deletion  syndrome,  with  an  estimated  incidence  of  1/5000
births[1].  The  previous  study showed that  the  deletion  size  and breakpoints  varies
widely from 1.5 Mb - >10 Mb, about 40% of all breakpoints occur 3.0-5.0 Mb from
the telomere, and 50% of individuals with 1p36 deletion syndrome have a terminal
deletion[2].  The  major  clinical  features  of  1p36  deletion  syndrome  patients
characterized  by a  variety of  generalized  hypotonia,  seizure,  prenatal  or  postnatal
growth restriction,  severe  developmental  delays,  facial  features  and CHDs [3,  4,  the
patients  may  also  show  skeletal  abnormalities,  fetal  akinesia, gastrointestinal
malformations,  cutis laxa, and biliary atresia[5-7].  Although 1p36 deletion syndrome
was  considered  clinically  recognizable,  there  was  significant  phenotypic  variation
among  affected  individuals,  patients  with  this  syndrome  should  undergo  a
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multidisciplinary evaluation and receive comprehensive follow-up treatment.
The deletion sizes of about 40% 1p36 terminal deletion patients are 3.0 - 5.0 Mb, so
traditional cytogenetic techniques including karyotype analysis and fluorescence in
situ hybridization (FISH) are insufficient good diagnostic tools. In recent years, CMA
is increasingly used in clinical genetics both in the postnatal and prenatal settings,
several studies have focused specifically on the use of CMA in prenatal diagnosis of
fetuses with abnormal ultrasound findings[8, 9], so more and more microdeletions and
microduplications  including  1p36  deletion  were  identified.  However,  only  a  few
prenatal  identified  cases  have  been  reported,  prenatal  diagnosis  and  genetic
counseling  are  challenging.  Sarah  Guterman  et  al.  reported  ten  new  cases  and
reviewed 22 prenatally diagnosed cases[10], Xun Zhang et al. also reported ten new
prenatal cases of 1p36 deletion[11], but not all cases with pure 1p36 terminal deletion
in previous studies. Therefore, more prenatal cases are necessary to delineate the fetal
manifestations  of  the  syndrome.  In our  present  study,  we present  three  new 1p36
terminal  deletion  cases  in  which  prenatal  ultrasonography  demonstrated  fetal
manifestations, objective to present the prenatal features associated with the terminal
chromosomal  deletion.  In  addition,  we  also  gathered  11 published prenatal
cases of the deletion size less than 5 Mb and compared these new cases
with the published data, further shed light on the genotypes and phenotypes.
Materials and methods
Case selection
This was a retrospective study,  we reviewed three  prenatal  cases  of  1p36
terminal deletion diagnosed at the First Affiliated Hospital of the Air Force Military
Medical University, from January 2015 to August 2019. Only cases with pure
1p36 terminal deletion were included. We also reviewed 11 published prenatal
cases of 1p36 terminal deletion with similar deletion sizes. Clinical data of
all  cases  including  maternal  factors,  sonographic  findings,  the  indication  for  the
invasive, duration of gestation at the time of diagnosis, and pregnancy outcomes were
reviewed and analyzed. 
Genomic DNA preparation 
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Amniotic  fluid  (20  ml)  was  sampled  by  amniocentesis  after  obtaining  informed
consent from the parents. Genomic DNA was extracted from amniotic fluid (10 ml)
by a  QIAamp DNA Blood Mini Kit  (Qiagen,  Venlo,  The Netherlands).  Nanodrop
2000 (Thermo Fisher  Scientific,  Waltham,  MA,  USA) was used for  detecting  the
concentration and quality of genomic DNA.
CMA
Cytoscan  750k  array  (Thermo  Fisher  Scientifc,  Santa  Clara,  CA,  USA)  with  an
average resolution of 100 kb for copy number variations (CNVs) was used according
to  the  standard  manufacturer’s  protocol.  The  public  Databases  such  as  OMIM
(http://www.ncbi.nlm.nih.gov/omim),  DECIPHER  (http://decipher.sanger.ac.uk/),
ISCA  (https://www.iscaconsortium.org/),  and  PubMed
(http://www.ncbi.nlm.nih.gov/pubmed/) were used for the interpretation of the results
and to analyze genotype-phenotype correlations. 
Results
In this study, only prenatal cases with a pure terminal deletion were enrolled. Three
cases  of  1p36  terminal  deletion  were  detected  because  of  abnormal  ultrasound
findings  including  CNS  abnormalities  and  CHDs.  G-band  karyotyping  of  them
showed  normal.  CMA  demonstrated  a  deletion  of  1.3  Mb  between
genomic  positions  849,466  and  2,121,139  (hg19)  at  1p36.33
including 32 OMIM genes in case 1. A deletion of 5.0 Mb and 4.9 Mb were
detected in case 2 and case 3 respectively, and 56 OMIM genes were included
in the region. The detailed descriptions of the new cases and published cases were
summarized in Table 1. CMA results were showed in figure 1.
We  followed  up  all  cases  by  telephone,  case  1  and  3  decided  to  terminate  the
pregnancy and case 2 remain selected to continue the pregnancy after detail genetic
counseling. Case 2 was born by cesarean section at 38th week of gestation with an
Apgar score of five at 1 min and five at 5 min, anoxia and respiratory weakness were
observed,  then  the  neonate  was  sent  to  the  NICU  for  treatment.  The  case  was
observed to have hypertelorism, and deep-set ears, feeding difficulties, poor hearing,
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hypotonia, seizures and developmental delay. In addition, patent ductus arteriosus and
patent foramen ovale were identified by postpartum echocardiography. Unfortunately,
the case died three months after birth. 
Discussion
Until  now, few cases of  prenatal  diagnosis  of  pure 1p36 terminal
deletion have been reported in the literature, especially those with a
deletion less than 5 Mb, suggesting that some cases might have
been underdiagnosed because of the low resolution karyotyping[12].
In  recent  years,  with  the  wide  application  of  genome-wide  high-
resolution CMA in prenatal diagnosis, more and more microdeletion
or  microduplication  syndromes  are  detected[13,  14].  In  the  current
study, we report three new cases of prenatal diagnosis of pure 1p36
terminal  deletion  detected  by  CMA,  and  gathered  11  published
prenatal cases of the deletion size within(less than) 5 Mb. We tried
to  identify  the  prenatal  clinical  manifestations  and  genotype-
phenotype relationship of pure 1p36 terminal deletion.
It  was noteworthy that CNS abnormalities are common ultrasonic
manifestations of pure 1p36 terminal deletion fetuses. In our new
cases  and  the  published  cases  one  or  more  CNS  abnormalities
including  ventriculomegaly,  agenesis  of  the  corpus  callosum and
cerebellar hypoplasia were observed in six of  the fourteen cases.
Prenatal  ultrasonography  revealed  CNS  abnormalities  for  fetuses
with  the  deletion  include  ventriculomegaly,  hydrocephalus,
interhemispheric cyst, abnormal sylvian fossa, cerebellar hypoplasia
and  agenesis  of  the  corpus  callosum.  The  most  common  CNS
abnormality  in  the  prenatal  ultrasonic  findings  was
ventriculomegaly,  four  fetuses  were  detected  with  isolated
ventriculomegaly  or  combined  with  other  abnormalities.  These
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findings  suggest  that  CMA  should  be  offered  to  fetuses  with
ventriculomegaly,  regardless  whether  or  not  other  structural
abnormalities  are  associated.  We  also  identified  a  case  with
agenesis of the corpus callosum that was rare in the literature. Our
findings  support  that  a  variety  of  brain  abnormalities  including
ventriculomegaly,  hydrocephalus,  and  agenesis  of  the  corpus
callosum associated with 1p36 deletion syndrome.
Congenital heart disease is also one of the most common clinical
manifestations in prenatal echocardiography examination of fetuses
with 1p36 deletion. Shino Shimada et al. study showed that CHDs
were  observed  in  69%,  patent  ductus  arteriosus  and  ventricular
septal defects were the most frequently observed patterns4], but not
all CHDs were prenatally identified. Seven cases were identified with
various  cardiac  anomalies  such  as  ventricular  septal  defect,
noncompaction  of  ventricular  myocardium,  double  outlet  right
ventricle, pulmonary valve stenosis in our new and the published
cases. In our case 3, noncompaction of ventricular myocardium was
identified  by  prenatal  echocardiography,  this  was  consistent  with
the previous study. In addition, there were many reports that reveal
the  association  between  ebstein  anomaly  and  1p36  terminal
deletion[15-17].  In  the  prenatal  study,  three  fetuses  with  ebstein
anomaly were detected, further provide the basis for 1p36 terminal
deletion  prenatal  diagnosis.  Therefore,  the  finding  of  cardiac
abnormalities poses a high risk of  1p36 terminal  deletion for the
fetus. The ventricular septal defect was detected at 28th week of
pregnancy in case 1, and CMA revealed a 1.3 Mb deletion in 1p36
terminal.  To  our  best  knowledge,  this  was  the  smallest  deletion
found before delivery, but 32 OMIM genes were included and many
of them such as GNB1, PRKCZ, GABRD are well defined. Previously
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studies  suggest  that  the  gene  GNB1 implicated  in  neurological
development[18]. The gene  PRKCZ was thought to be necessary for
regulating  axonal  differentiation  and  had  been  implicated  in  a
variety  of  processes  including  cardiac  muscle  function[19,  20]. The
gene GABRD encodes the subunit of the GABAA receptors, plays an
important  role  in  mammalian  brain  development,  and
haploinsufficiency  may  be  responsible  for  neurologic  features[21].
Previous  studies  showed that  even  a  small  deletion  at  the  1p36
terminal  might  lead  to  phenotypic  alteration[22].  Considering  the
possible  clinical  manifestations  such  as  developmental  delay,
mental retardation and CHDs, the couple decided to terminate the
pregnancy after detailed genetic counseling. Characterization of the
prenatal  case  with  small  deletion  is  helpful  for  narrowing  critical
intervals of 1p36 deletion syndrome.
The  prenatal  diagnosis  of  1p36  terminal  deletion  is  a  challenge
because  of  the  variability  clinical  manifestations  and  depends
largely  on  the  gestational  age  when  the  diagnosis  was  made.
Though CNS abnormalities and cardiac abnormalities could be the
most common features in prenatal 1p36 terminal deletion cases, the
prenatal ultrasound features of 1p36 terminal deletion remain non-
specific.  When cases  with  ultrasound findings  such as  congenital
heart defects, ventriculomegaly, agenesis of the corpus callosum, a
clinical  suspicion  of  1p36  terminal  deletion  or  other
microdeletion/microduplication syndromes should be considered. In
addition, isolated abnormalities such as ventriculomegaly may not
attract  the  attention  of  pregnant  women,  so  the  best  time  for
invasive prenatal diagnosis was missed. We suggest that cases with
ultrasound findings such as CHDs, ventriculomegaly, agenesis of the
corpus  callosum  should  alert  clinicians  to  the  possibility  of
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chromosome  1p36  deletion  syndrome  or  other
microdeletion/duplication syndromes.
In conclusion, CMA is an effective method for the precise diagnosis
of 1p36 terminal deletion. We summarized the characteristics and
prenatal clinical findings of fetuses with pure 1p36 terminal deletion,
aim to emphasize the importance of CMA in detecting chromosomal
abnormalities and provide a basis for prenatal diagnosis. Since 1p36
terminal deletion is associated with a poor prognosis in general and
severe intellectual disability in particular, the prenatal diagnosis of
this condition may help parents to decide whether to continue or to
terminate the pregnancy.
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Fig 1. The CMA profile of the 1p36 microdeletions were represented by the bold red line. OMIM genes were listed at the bottom, dark green can be disease-















1 32 32+4 VSD 46, XX arr[GRCh37] 1p36.33(849,466_2,121,139)x1 1.3 Unknown TOP
2 33 23+1 ACC, polyhydramnios 46, XX arr[GRCh37]
1p36.33p36.31(849,466_5,851,366)x1
5.0 De novo Born, death



















36 13 Retrognathia 46, XX arr[GRCh37]
1p36.33p36.2(779,727_4,859,438)x1




30 26 Bilateral VMG, abnormal
sylvian fossa, cerebellar
hypoplasia
46, XY arr[GRCh37] 1p36.33(834101_2225782)x1 1.4 De novo TOP
Xun Zhang
et al 3
45 11 NT: 1.4 mm 46, XY arr[GRCh37]1p36.33p36.32(849,466_2,516,03
1)x1
1.7 De novo TOP
Xun Zhang
et al 4
30 17 NT: 1.7 mm, cfDNA:
high risk for 1p_
46, XX arr[GRCh37]1p36.33p36.31(849,466_6,374,40
7)×1
5.5 De novo TOP
Xun Zhang
et al 5
27 22 Ebstein anomaly 46, XX arr[GRCh37]1p36.33p36.31(849,466_6,927,02
6)×1
6.1 De novo TOP
Xun Zhang
et al 6
30 22 DORV, PVS, VSD 46, XX arr[GRCh37]1p36.33p36.32(849,466_5,383,95
6)×1
4.5 De novo TOP
Xun Zhang
et al 7
30 23 Ebstein anomaly,VSD 46, XY arr[GRCh37]1p36.32p36.22(1,397,489_3,628,0
23)×1
2.3 De novo TOP
Xun Zhang
et al 8
31 30 Bilateral VMG (13mm) 46, XY arr[GRCh37]1p36.33p36.31(849,466_6,435,58
3)×1





















NA NA VSD, DORV, PS NA arr[GRCh37][hg]1p36.33p36.32
(849,466_5,383,956)x1
4.5 De novo NA
Abbreviations: VSD, ventricular septal defect; ACC, agenesis of the corpus callosum; NVM, noncompaction of ventricular myocardium; TOP, Termination of
pregnancy; AMA, advance maternal age; cfDNA, cell-free DNA; DORV, double outlet right ventricle; NA, not available; NT, nuchal translucency; PVS,
Pulmonary valve stenosis; PS, Pulmonary stenosis; TOP, termination of pregnancy; VMG, ventriculomegaly; CPCs, choroid plexus cysts; FGR, fetal growth
restriction;
